Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Junshi Biosciences
Pharma
Takeda, AZ-Daiichi, Fosun-Henlius—Fierce Pharma Asia
Takeda's R&D chief explained his new investment priorities. AZ and Daiichi's TROP2 ADC cleared the FDA. Fosun failed to buy out Henlius. And more.
Angus Liu
Jan 24, 2025 8:55am
Leo bags Loqtorzi rights, putting marketing muscle behind launch
Jan 21, 2025 11:15am
AbbVie-FutureGen, Takeda, Kyowa Kirin—Fierce Pharma Asia
Jun 14, 2024 5:00am
Junshi, Coherus move Loqtorzi closer to another approval
Jun 12, 2024 11:45am
AstraZeneca, BeiGene, Coherus—Fierce Pharma Asia
Dec 1, 2023 8:34am
Coherus prices China-made PD-1 at 20% discount to Keytruda
Nov 27, 2023 6:10pm